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Introduction 
 
Colorectal cancer (CRC) is the third most commonly 
diagnosed cancer in men and women worldwide (1). 
CRC has multiple clinical pathologies that allow for 
effective staging and classification when considering 
treatment. For instance, among the clinical signs 
assessed include the tumor volume, presence of lymph 
node metastasis, blood vessels, lymphovascular 
invasion and perineural invasion. Lymphovascular 
invasion (LVI) is one of the most critical steps in 
metastasis and the process involves the invasion of 
tumor cells in the lymphatic spaces, blood vessels or 
both in the peritumoral area (2). Moreover, LVI has 
been linked to other cellular pathways such as 
angiogenesis, cell proliferation and cell migration (3). 
LVI is associated with a wide variety of cancers 
including breast cancer (3), endometrial cancer (4), 
prostate cancer (5), gastric cancer (6) and CRC (7, 8). 
The usage of LVI as a prognostic marker for survival 
in a number of different cancers, especially CRC, has 
been widely studied (9-11). In fact, the presence of 
LVI has been a factor for clinicians to consider before 
making an informed decision regarding treatment (12, 
13). For instance, in invasive breast carcinoma, the 
presence of LVI can be used to identify which 
adjuvant treatment is suitable (12, 14). Similarly in 
papillary thyroid carcinoma, patients with LVI are 
strongly recommended to receive post-operative 
radioactive iodine (RAI) therapy to have a better 
outcome (13).  
 
Besides LVI, perineural invasion (PNI) is also an 
important factor in determining treatment and survival 
rates (9). PNI is a process whereby cancer cells 
migrate and invade the surrounding nerves (15). PNI 
was first discovered in head and neck cancer, however, 
to date, multiple other types of cancer cells have been 
reported to be able to invade the perineural site as well 
(15, 16). For instance, in prostate cancer, it has been 
well established that PNI contributes to cancer 
aggressiveness and subsequently, lower survival rates 
(17-19). In CRC, the presence of PNI is associated 
with a wide range pathological features such as poor 
tumor differentiation, high grade tumor classification 
and aggressive tumor behavior (7, 20, 21). PNI 
assessment has not been a major aspect in the 
stratification of CRC patients. However, recently, it 
has been reported that PNI deserves extra attention 
especially as a prognostic factor (22). In terms of 
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therapy in CRC patients, PNI should also be given 
considerable attention in influencing the treatment 
given (23). 
 
Adjuvant therapy for CRC patients are usually given 
based on the presence of clinical signs such as LVI, 
PNI or presence of secondary tumors (24, 25). There 
have been studies conducted that assessed the efficacy 
of a treatment based on different types of clinical 
pathology (25). Nevertheless, in this post-genomic era, 
besides assessing the clinical signs, we also need to 
correlate it with the molecular profile of each tumor. 
Since CRC, as with any other cancer, is known to be 
molecularly and clinically heterogeneous, combining 
both information would allow 
oncologists to execute a more 
comprehensive treatment 
approach. However, the 
concomitant existence of both 
LVI and PNI in CRC may 
make it more difficult to treat 
and compare. For instance, in a 
Swedish cohort of rectal cancer 
patients, it was discovered that 
the rate of recurrence was 
higher in patients having both 
LVI and PNI instead of just 
having either LVI or PNI (26). 
Similarly, it was reported that 
the overall survival rate was 
much lower in gastric cancer 
patients having both LVI and 
PNI (27). 
Therefore, in an effort to 
determine the concomitant 
existence of LVI and PNI in 
CRC, we re-analyzed The 
Cancer Genome Atlas (TCGA) 
data based on the molecular 
profile of LVI and/or PNI. We 
performed analysis related to 
gene expression, methylation profile and miRNA 
expression by comparing CRC patients with LVI 
and/or PNI against patients without LVI and PNI. We 
identified differentially expressed genes that could be 
used to further understand the molecular profiles of 
tumors with invasive behavior. 
 




A total of 456 datasets corresponding to colon 
adenocarcinoma (COAD) cases (cite Cancer Genome 
Atlas Research Network, 2012) were downloaded 
from the TCGA portal in April 2017. Methylation data 
based on Illumina Methylation 450 beadchip in β 
value format was retrieved from cBioPortal 
(http://www.cbioportal.org/data_sets.jsp) while level 
3 RNA sequencing dataset in RSEM (RNA-Seq by 
Expectation Maximization) format and microRNA 
sequencing in normalized reads per million (RPM) 
format were retrieved from Firebrowse 
(doi:10.7908/C1F76BX1). TCGA CRC patients’ 
information were obtained from GDC  Data Portal 
(https://portal.gdc.cancer.gov/). From there, we 
filtered for the presence of lymphovascular invasion 
(LVI) and perineural invasion (PNI) status, where we 
excluded 280 datasets due to the lack of information 
regarding LVI and PNI invasion status.  
 
The final number of datasets used for the analysis was 
176, where we divided it into 4 groups. The groups are 
LVI+PNI+ (presence of both LVI and PNI), LVI-
PNI+ (absence of LVI and presence of PNI), 
LVI+PNI- (presence of LVI and absence of PNI) and 
LVI-PNI- (absence of both LVI and PNI). The 
patients’ characteristics and clinicopathological 




Kaplan-Meier survival analyses were performed for 
the overall survival analysis (OS) and disease-free 
survival analysis (DFS) for patients with follow-up 
details. The OS analysis was conducted based on the 
 
Table 1: Clinicopathological characteristics of the patients involved in the analysis. 
a p-value for the chi-square tests comparing all groups 




duration from date of diagnosis to death, while for the 
DFS analysis, the duration was selected from the date 
of diagnosis to the event of relapse or recurrence (28). 
All the analyses were conducted on Graph Pad Prism 
software version 7.00 (Graphpad Prism, USA) using 




The miRNAseq and RNAseq level 
3 datasets and methylation dataset 
from TCGA were used exclusively. 
For the RNAseq analysis, we used 
the RNAseq by Expectation-
Maximization (RSEM) values to 
quantify the expression level of 
mRNAs. Additionally, for the 
miRNAseq analysis, we used the 
normalized reads per million 
(RPM) for quantification. 
Afterwards, we performed the 
Students unpaired t-test using the 
Benjamini Hochberg (HB) false 
discovery rate (FDR) multiple 
testing correction using the 
Bioconducter in R version 3.2.1. 
We then calculated the log2 fold 
change based on the mean 
expression of normalized log2 
values for each category. Statistical 
significance was set at 
P≤0.05.Heatmaps were generated 
using Morpheus from the Broad Institute 
(https://software.broadinstitute.org/morpheus/). Venn 
diagrams were created using an online maker tool at 
(http://bioinformatics.psb.ugent.be/webtools/Venn/). 
The overall study design is displayed in Figure 1. 
 
Pathway enrichment analyses and gene ontology 
analyses 
 
Pathway enrichment and gene ontology analysis were 
performed using the online tool WEB-based GEne 
SeT AnaLysis Toolkit v. 2017 (WebGestalt) 
(www.webgestalt.org)(29). For the LVI+PNI+ 
comparison group, the input list contained 72 
differentially expressed genes with P value ≤0.05, 
from which 69 genes were unambiguously mapped to 
the unique Entrez Gene IDs and 3 genes were mapped 
to multiple Entrez Gene IDs or could not be mapped 
to any Entrez Gene ID. For the LVI-PNI+ comparison 
group, the input list contained 43 differentially 
expressed genes with P value≤0.05, form which 39 
genes were mapped to the unique Entrez Gene IDs and 
4 genes were mapped to multiple Entrez Gene ID or 
could not be mapped to any Entrez Gene ID. All 
mapped Entrez Gene IDs were retrieved from the 
platform genome_protein-coding. The minimum 
number of Entrez Gene IDs in the category was set at 
5. The FDR method used was BH. Moreover, we also 
performed the analyses using the Database for 
Annotation, Visualization and Integrated Discovery 
(DAVID) as a comparison. The pathway enrichment  
 
analysis was performed based on the Kyoto 
Encyclopedia of Genes and Genomes (KEGG) 
database (30), and the gene ontology analysis was 
performed based on the biological process and 
molecular function. Analyses with Benjamini-




Clinicopathological characteristics of CRC patients 
with LVI and/or PNI 
 
Overall, a total of 176 CRC patients were used for this 
analysis, where 24 were in the LVI+PNI+ group, 22 
for the LVI-PNI+ group, 28 for the LVI+PNI- group 
and 102 for the LVI-PNI-group. Based on the 
demographic and clinicopathological features 
displayed in Table 1, there were considerable 
differences in the disease-free status, overall survival 






Figure 1. Overall study design using TCGA datasets. 
 




The effects of LVI and PNI on the overall survival 
and disease-free survival analyses in CRC patients 
 
As illustrated in Table 1, among the four groups, LVI-
PNI+ group had the lowest mean overall survival (OS) 
with 22.11 months, whereas the highest mean OS was 
LVI-PNI- group with 29.69 months. However, even 
though LVI-PNI+ patients had the lowest mean OS, 
the Kaplan-Meier survival curve was not significant 
against patients with LVI-PNI- (Log rank Mantel Cox 
Test, P=0.1792, Figure 2A).  Meanwhile, for patients 
with LVI-PNI+, there was no statistically significant 
difference in terms of OS against patients with LVI-
PNI- (Log rank Mantel-Cox Test, p=0.728, Figure 
2B). Based on our Kaplan-Meier survival curve 
analysis as shown in Figure 2, patients who had both 
LVI and PNI (LVI+PNI+) had a lower OS rate as 
compared to patients who did not have LVI and PNI 
(LVI-PNI-) (Log rank Mantel-Cox Test, P=0.004, 
Figure 2C). Similarly, for the mean disease-free 
survival, LVI-PNI+ group had the lowest value with 
17.89 months. However, interestingly, the LVI+PNI-
group had the highest mean disease-free survival with 
29.33 months compared to the LVI-PNI- group. As 
Figure 2. A-C, Overall survival (OS) analysis for A) LVI+PNI- against LVI-PNI-, B)LVI-PNI+ against LVI-PNI-, C) LVI+PNI+ 
against LVI-PNI-. D-F, Disease-free survival analysis (DFS) for D) LVI+PNI- against LVI-PNI-, E) LVI-PNI+ against LVI-PNI-
, F) LVI+PNI+ against LVI-PNI-. 
 




displayed in Figure 2F, the DFS for LVI+PNI+ against 
LVI-PNI- was not statistically significant (Log rank 
Mantel Cox Test, P=0.138). Likewise, when 
comparing LVI+PNI- against LVI-PNI-, no statistical 
significance was observed (Log rank Mantel Cox Test, 
P=0.104, Figure 2D). Interestingly, for the comparison 
of LVI-PNI+ against LVI-PNI-, the P value obtained 
was 0.0015, making the DFS curves significantly 
different (Figure 2E). 
 
Differentially expressed genes (DEGs) 
 
Based on the RNAseq reanalysis, only the 
LVI+PNI+/LVI-PNI- group and LVI-PNI+/LVI-PNI- 
group have differentially expressed genes (DEGs) 
with P values ≤ 0.05. According to Table 2, the 
LVI+PNI+/LVI-PNI- group had 76 differentially 
expressed genes, but 4 had to be eliminated from the 
analysis due to the low level of expression. The genes 
with log2 fold change more than 1.4 include SFTA2, 
PHACTR3, CRABP2, ODZ3, GRP, HAP1 CSDC2, 
HDAC9 and TMEM59L. The comparison of LVI-
PNI+ against LVI-PNI- group produced 50 DEGs, but 
8 had to be removed due to the low expression as 
shown in Table 3.  
 

















SFTA2 389376 5.793 3.701 2.092 0.050 
PHACTR3 116154 5.944 4.101 1.843 0.049 
CRABP2 1382 7.501 5.760 1.741 0.044 
ODZ3 55714 6.982 5.306 1.676 0.049 
GRP 2922 5.221 3.628 1.593 0.050 
HAP1 9001 3.919 2.350 1.568 0.042 
CSDC2 27254 5.598 4.125 1.474 0.050 
HDAC9 9734 6.849 5.420 1.429 0.042 
TMEM59L 25789 3.337 1.917 1.420 0.050 
APOE 348 11.369 9.990 1.379 0.050 
SPOCD1 90853 6.559 5.205 1.354 0.042 
KCNK15 60598 3.990 2.644 1.346 0.049 
NAV3 89795 4.990 3.769 1.221 0.042 
CATSPER1 117144 2.775 1.561 1.214 0.042 
ANGPTL4 51129 8.042 6.843 1.199 0.050 
ARL4C 10123 10.304 9.124 1.180 0.036 
HS3ST2 9956 4.322 3.151 1.171 0.050 
PLA2G16 11145 9.870 8.709 1.161 0.036 
KCNE4 23704 7.555 6.399 1.156 0.050 
FSTL3 10272 9.645 8.495 1.150 0.042 
BAALC 79870 3.839 2.702 1.137 0.050 
SLC2A3 6515 9.953 8.823 1.130 0.042 
TRPC1 7220 5.741 4.624 1.116 0.049 
CCDC136 64753 5.297 4.181 1.116 0.044 
AG2 387763 9.134 8.029 1.105 0.050 
GULP1 51454 7.869 6.769 1.100 0.042 
GRID1 2894 4.873 3.775 1.098 0.044 
ADAMTS4 9507 9.415 8.334 1.081 0.042 
SPIRE1 56907 8.845 7.776 1.070 0.036 
SLC22A17 51310 7.020 5.951 1.069 0.050 
ITGA5 3678 11.420 10.388 1.032 0.050 
C10orf114 399726 3.665 2.677 0.988 0.050 
SV2A 9900 6.376 5.393 0.983 0.042 
C10orf10 11067 10.013 9.041 0.972 0.050 
RNF217 154214 5.961 4.996 0.964 0.050 
DTX3 196403 7.806 6.847 0.959 0.038 
TRIM6 117854 5.356 4.412 0.944 0.049 
FAM127A 8933 9.781 8.862 0.920 0.050 
HCG11 493812 8.390 7.486 0.904 0.038 
TSC22D3 1831 10.558 9.659 0.899 0.050 
KLF7 8609 7.085 6.192 0.893 0.038 
STC1 6781 8.835 7.945 0.890 0.042 
FCRLB 127943 4.293 3.424 0.868 0.044 
NOTCH3 4854 11.288 10.421 0.867 0.042 
TICAM2 353376 6.277 5.419 0.859 0.050 
PRR16 51334 5.967 5.131 0.836 0.050 
MDFI 4188 8.569 7.740 0.829 0.029 
SYDE1 85360 8.363 7.557 0.806 0.042 
PDLIM7 9260 10.419 9.632 0.787 0.049 
C2orf16 84226 4.657 3.878 0.779 0.050 
OSBPL1A 114876 9.046 8.271 0.775 0.050 
GADD45B 4616 9.220 8.473 0.747 0.050 
LATS2 26524 9.077 8.352 0.724 0.050 
PIM1 5292 10.255 9.532 0.723 0.042 
RAI14 26064 9.967 9.263 0.704 0.044 
BICD1 636 7.233 6.560 0.673 0.050 
CYGB 114757 8.863 8.206 0.656 0.044 
HOOK3 84376 9.788 9.148 0.641 0.042 
PLEKHG2 64857 9.011 8.373 0.638 0.050 
ZNF75A 7627 7.256 6.683 0.573 0.049 
RRAS 6237 10.324 9.815 0.509 0.046 
SLC20A1 6574 10.631 10.169 0.463 0.050 
CYTH1 9267 10.120 9.770 0.350 0.042 
RPP14 11102 9.029 9.272 -0.243 0.044 
CNOT10 25904 9.157 9.409 -0.253 0.050 
CDC40 51362 9.055 9.318 -0.263 0.044 
SLC25A38 54977 9.482 9.752 -0.270 0.050 
GLB1 2720 10.868 11.201 -0.333 0.042 
ATPAF1 64756 9.689 10.029 -0.340 0.042 
CMC1 152100 7.696 8.116 -0.420 0.050 
GFM2 84340 8.845 9.328 -0.483 0.044 
GSR 2936 10.012 10.628 -0.616 0.050 
 
















PTPRR 5801 7.919 6.564 1.355 0.026 
EFNA2 1943 6.628 5.397 1.231 0.026 
METRN 79006 8.368 7.163 1.206 0.038 
POMZP3 22932 7.601 6.666 0.935 0.046 
TIMM16 51025 9.082 8.231 0.851 0.044 
C17orf67 339210 5.036 4.219 0.817 0.035 
TIGD3 220359 4.813 4.023 0.789 0.026 
C11orf83 790955 9.773 8.993 0.780 0.046 
CENPM 79019 9.061 8.301 0.761 0.049 
RHEBL1 121268 5.604 4.874 0.730 0.030 
C16orf48 84080 8.514 7.796 0.718 0.004 
GPX4 2879 11.732 11.028 0.704 0.046 
TK1 7083 11.149 10.449 0.700 0.046 
YDJC 150223 9.816 9.153 0.663 0.027 
H1FX 8971 11.222 10.607 0.615 0.026 
DHRS13 147015 8.119 7.512 0.608 0.047 
ARL2 402 10.803 10.245 0.558 0.050 
SLC25A39 51629 12.545 11.996 0.549 0.026 
CDK2AP2 10263 10.768 10.242 0.526 0.046 
EME1 146956 6.879 6.356 0.523 0.046 
LOC93622 93622 8.413 7.892 0.520 0.028 
NAGPA 51172 8.949 8.436 0.513 0.046 
PPP1CA 5499 12.568 12.061 0.507 0.049 
LSM4 25804 11.821 11.316 0.505 0.046 
ECSIT 51295 10.232 9.740 0.492 0.046 
CBX8 57332 8.517 8.028 0.489 0.046 
THAP7 80764 8.720 8.249 0.472 0.035 
ACD 65057 9.357 8.888 0.469 0.046 
HCFC1R1 54985 9.169 8.706 0.463 0.044 
C11orf68 83638 9.659 9.263 0.396 0.041 
FAM98A 25940 9.746 10.035 -0.289 0.046 
NFX1 4799 9.669 10.020 -0.351 0.049 
C10orf137 26098 7.776 8.295 -0.519 0.046 
EIF2AK3 9451 8.785 9.325 -0.540 0.046 
VANGL1 81839 9.199 9.761 -0.562 0.046 
SYK 6850 10.452 11.027 -0.575 0.046 
USP37 57695 9.030 9.624 -0.594 0.046 
USP8 9101 9.501 10.114 -0.613 0.046 
SERPINA1
1 
256394 0.312 1.152 -0.840 0.036 
KCNA2 3737 0.582 1.464 -0.881 0.041 
IGFL4 444882 0.706 1.915 -1.209 0.015 
IGFBPL1 347252 0.578 1.822 -1.245 0.026 
FGF20 26281 0.371 1.629 -1.258 0.007 




Genes that had fold changes of more than log2 1.2 were 
EFNA2, PTPRR, METRN (up-regulated genes) and 




Figure 3: A) Heatmap visualization of the DEGs in 
LVI+PNI+ group against LVI-PNI-. B) Heatmap 
visualization of the DEGs in LVI-PNI+ group against LVI-
PNI-. C) Venn diagram of the DEGs found in all groups. 
 
The heatmap visualization for both sets of genes is 
displayed in Figure 3A and 3B. For the comparison of 
LVI+PNI- against LVI-PNI-, no significant DEGs 
were observed, so we reduced the stringency, and set 
the P value at p≤0.1. From there, only 32 DEGs were 
identified, where 5 genes were removed due to the low 
level of expression. Interestingly, as shown in Figure 
3C, based on the two sets of genes, there were no 
overlapping genes observed in all two sets. Only 9 
genes were found to be overlapping between the LVI-
PNI+ set and LVI+PNI-set. The overlapped genes are 
ARL2, C11orf68, C11orf83, C17orf67, EIF2AK3, 
POMZP3, SLC25A39, SYK and THAP7. 
 
 Gene Ontology and Pathway Enrichment Analysis 
 
The gene ontology analyses were performed using the 
DEGs discovered in the two sets of genes as shown in 
Table 4. We used both the WebGestalt and the DAVID 
program as a comparison in terms of the statistical 
significance. For the first set of comparison group 
(LVI+PNI+/LVI-PNI-), only 1 pathway was found to 
be enriched, which is the pathway related to 
microRNAs in cancer.  
 
However, only the WebGestalt application managed to 
identify this pathway. Next, we performed gene 
ontology analysis, for the biological process, where 
angiogenesis and regulation of calcium ion were 
significantly enriched. For the molecular function, 
most of the genes were involved in transporter-related 
activity. In the second set of genes (LVI-PNI+/LVI-
PNI-), the enriched pathways were MAPK and PI3K-
AKT pathways. For the gene ontology analysis, the 
enriched biological process were transmembrane 
receptor tyrosine kinase pathway and ammonium 
transport. Meanwhile for the molecular function, the 
phosphatase binding function was enriched.  
 
Methylation and miRNA analyses 
 
We also reanalyzed the global methylation and 
miRNA differential expression analysis for each of the 
comparison groups. However, no significant 
difference (P≤0.05) in the methylation status were 
found. Similarly, for the miRNA expression, there 





In this study, we analyzed the gene expression data of 
the concomitant existence of lymphovascular invasion 
(LVI) and/or perineural invasion (PNI) in colorectal 
cancer (CRC) patients using the Cancer Genome Atlas 
(TCGA) dataset.  
 
For the overall survival analysis (OS), only the 
LVI+PNI+ group showed a statistically significant 
difference in terms of survival than the LVI-PNI- 
group. This indicates that CRC patients with both LVI 
and PNI have a shorter survival rate than patients with 
either LVI only or PNI only. Interestingly, even 
though the OS for the LVI+PNI+ CRC patients was 
more significantly affected, the patients with LVI-
PNI+ showed a higher tendency of 
recurring/progressing according to the DFS analysis. 
In gastric cancer patients, it was reported that only 
LVI+PNI+ patients had a significant difference in 
DFS and OS rate than the other groups (27). This 
suggests that in different types of cancer, both LVI and 
PNI play ultimately different roles with regards to the 
OS and DFS.  
 




From the gene expression analysis, a total of 72 
differentially expressed genes (DEGs) were 
discovered in the LVI+PNI+ vs LVI-PNI- 
comparison. Of all the deregulated genes, SFTA2 had 
the highest difference in terms of fold change. SFTA2 
or also known as “surfactant associated 2” has been 
reported to be overexpressed in lung cancer (31). 
SFTA2 was predicted to interact with other mucin-like 
proteins that are highly abundant in the lung (31). It 
was only recently that SFTA2 was proposed as a 
biomarker to differentiate between lung 
adenocarcinoma and squamous cell carcinoma (32). 
However, not much research has been conducted to 
evaluate the molecular function of SFTA2 in regard to 
carcinogenesis especially in relation to LVI and PNI.  
Another gene that was upregulated in the LVI+PNI+ 
vs LVI-PNI- group is the phosphatase and actin 
regulator 3 (PHACTR3) gene. This gene is part of the 
PHACTR family which is highly involved in the 
reorganization of the cytoskeleton and actin (33). It 
was reported that PHACTR3 enhances cell motility 
and adhesion of HeLa cells by interacting with the 
actin cytoskeleton (34). This is in concordance with 
our hypothesis, since LVI+PNI+ patients have a 
higher rate of metastasis, proteins related to the 
movement of cancer cells should be elevated. A study 
conducted by Bosch et al found that the mRNA 
expression of PHACTR3 gene was low in CRC 
samples and significantly hypermethylated in 
advanced CRC than in normal colonic mucosa (35). In 
our study however, the expression of PHACTR3 was 
higher in advanced CRC (LVI+PNI+), and there was 
no significant difference in terms of the methylation 
status. This reflects the molecular heterogeneity in 
CRC and could explain why these findings contradict 
each other. 
 
Another interesting finding from the LVI+PNI+ vs 
LVI-PNI- comparison is the upregulation of CRABP2. 
CRABP2, known as Cellular Retinoic Acid Binding 
Protein 2, is a member of the retinoic acid and 
cytosolic fatty-acid binding protein family (36, 37). 
This gene functions by transporting vitamin A to 
retinoic acid receptors and shuffling the complexes 
between the cytoplasm and nucleus (36-39). In cancer 
however, there have been multiple contradicting 
reports as to whether CRABP2 is involved in the pro-
tumorigenic or anti-tumorigenic process (36, 38, 39). 
In pancreatic cancer, a study conducted by Xiao et al 
found that CRABP2 could be used as a molecular 
Table 4: Pathway enrichment and gene ontology enrichment for the 2 DEGs datasets. 




marker for distinguishing the high grade pancreatic 
ductal adenocarcinoma cases from benign pancreatic 
conditions (38). This shows that CRABP2 is highly 
expressed in advanced pancreatic cancer, similar to 
what we have discovered in CRC. Additionally, in 
non-small lung cancer cells (NSCLC) patients, the 
expression of CRABP2 was also found to be 
upregulated (40). Favorskaya et al reported that the 
mRNA expression of CRABP2 was negatively 
correlated with the presence of lymph node metastasis 
in NSCLC patients (40). Interestingly, in our report, 
the LVI+PNI+ group had the highest presence of 
lymph node metastasis, and also a higher expression 
of CRABP2. This shows that the role of CRABP2 in 
different tumors is still not fully understood yet. 
Moreover, the expression of CRABP2 was shown to be 
significantly down regulated in esophageal cancer, 
confirming the unknown molecular dynamics of 
CRABP2 in different types of cancer (39). Besides 
CRABP2, the ODZ3 gene was also upregulated in 
LVI+PNI+ group. Little is known about ODZ3 except 
that it is part of the teneurins family, a group of highly 
conserved transmembrane proteins involved in 
intracellular signaling related to neural circuits and 
development (41, 42). In fact, ODZ3 was found to be 
heavily involved in microphthalmia in humans (43). In 
cancer, it was reported that ODZ3 was significantly 
mutated in colorectal cancer tissue (44-46). Apart 
from that, the molecular function of ODZ3 in relation 
to LVI and PNI is still elusive. 
 
The gastrin-releasing peptide (GRP) was also 
discovered to be overexpressed in the LVI+PNI+ 
group. This gene is known to be involved in multiple 
types of cancer including breast cancer (47), 
esophageal squamous cell carcinoma (48) and colon 
cancer (49). GRP acts as a growth factor by binding to 
GRP-receptors (GRPR) and is involved in other types 
of growth factor receptor signaling pathways such as 
EGFR and VEGFR (50). Molecules involved in 
growth factor signaling are highly associated with 
metastasis, angiogenesis and invasion. In fact, it was 
suggested that GRP and GRPR are involved in 
neoangiogenesis and microvascular perfusion in renal 
cell carcinoma (51). Moreover, a study conducted by 
Fleishcmann et al showed that GRPRs can be 
promising targets for vascular targeting applications 
since they are highly expressed in the vascular bed of 
various cancers (52). In CRC, a correlation was found 
between the high levels of mRNA of GRPR and 
lymphatic vessel invasion (45). This is similar to what 
we have discovered, where patients with more 
invasive CRC have a higher expression of GRP.  
 
The CSDC2 gene was also upregulated in regards to 
the LVI and PNI status in CRC. Nevertheless, there 
have been no reports on the function of CSDC2 in 
relation to CRC or any other types of cancer. Another 
gene that was upregulated was the TMEM59L gene. 
This gene is known to be involved in neuron-related 
pathways that modulates cellular oxidative stress (53). 
In terms of cancer, similar to the CSDC2 gene, there 
were limited information regarding its role in cancer.  
Since we did not find any significant difference in the 
methylation and miRNA profiles among all the 
groups, we hypothesized that there should be another 
epigenetic mechanism regulating the gene expression, 
such as long noncoding RNA or the recently 
discovered circular RNA. In the LVI+PNI+ vs LVI-
PNI- gene set, we found that HDAC9, or histone 
deacetylase 9 gene was significantly upregulated. 
HDAC9 is part of the histone deacetylases that are 
commonly deregulated in tumorigenesis and are 
epigenetically involved in multiple gene regulation. In 
fact, HDAC9 has been reported to be overexpressed in 
different types of tumor including breast cancer (54) 
and oral squamous cell carcinoma (55). HDAC9 was 
found to be targeting several genes including SOX9 
(54) and TRIM29 (56). In CRC, the inhibition of 
HDACs was shown to decrease the expression of 
EGFR. This could be particularly beneficial for 
patients who have the mutant KRAS where cetuximab 
is rendered inefficient (57). Thus knowing that 
HDAC9 is overexpressed in LVI+PNI+ patients could 
provide a more informed decision in treating these 
patients.  
 
We also found 42 DEGs when comparing the LVI-
PNI+ group against the LVI-PNI- group. In this set of 
genes, it was discovered that the PTPRR gene is 
significantly upregulated. This gene codes for the 
protein tyrosine phosphatase receptor-type R enzyme 
and is part of the protein tyrosine phosphatase (PTP) 
family (58). The PTPs are often involved in multiple 
signaling pathways including MAPK, ERK, cell 
growth and cell cycle-related pathways. PTPRR has 
been primarily viewed as a neuronal phosphatase 
which regulates the ERK pathway and it has been 
associated with major depressive disorder (MDD) 
(59). In cancer, interestingly, the levels of PTPRR is 
inversely correlated with the tumor grade. For 
instance, in oral squamous cell carcinoma (OSCC), the 
expression of PTPRR is higher in lower grades of 
OSCC and vice versa (60). Similarly, in CRC, the 
expression of PTPRR is decreased in CRC tissue and 
cell lines as compared to normal samples (61). In fact, 
Menigetti et al also reported that PTPRR is 
epigenetically silenced in the early events of CRC 
carcinogenesis. However, in our findings, we found 
that patients who were PNI positive, had a high 
expression of PTPRR than patients who were negative 
for PNI. Since, PNI is a process involving the neural 




network, it could be postulated that PTPRR could be 
reactivated upon PNI. However, further studies need 
to be conducted to conclusively understand the dual 
roles of PTPRR in CRC.  
 
Besides PTPRR, the EFNA2 gene was also increased 
in the LVI-PNI+ group. EFNA2 is the gene encoding 
the Ephrin-A2 protein, a member of the ephrin family. 
The ephrin family can be divided into ephrin A and 
ephrin B depending on the type of ligands they bind 
to. In prostate cancer, it has been shown that ephrin A 
modulates the contact inhibition of locomotion (62). It 
has also been reported that in a  Japanese patient 
diagnosed with adenoid cystic carcinoma, the 
expression of ephrin A2 was high and is associated 
with the clinical feature of perineural invasion (63). 
This was in agreement with our findings where PNI in 
CRC is correlated with the ephrin A2 expression. 
Another gene that was upregulated in this group 
comparison is the METRN gene. This gene codes for 
the meteorin protein, ans has been shown to be 
involved in the neurogenesis of glial cells (64). Apart 
from that, no other studies have reported on the 
function of this gene, much less in cancer. 
 
For the downregulated genes in LVI-PNI+ group, the 
three most significant ones are FGF20, IGFBPL1 and 
IGFL4. FGF20, also known as fibroblast growth factor 
20, is part of the fibroblast growth factor (FGF) family 
(65). In normal human tissues, FGF20 is highly 
expressed in the brain, especially in the cerebellum 
(65). FGF20 was also found to be overexpressed in 
SW480 colon cancer cell line, LXI liver cancer cell 
line and NCI-N87 gastric cancer cell line (65). 
However, there are few studies which have been 
performed to understand the role of FGF20, especially 
in terms of its relationship with perineural invasion.  
 
Furthermore, IGFBPL1, or insulin-like growth factor 
binding protein-related protein 1, is a member of the 
IGFBP superfamily that affects the expression of IGF-
1 and IGF-2 (66). This protein has been reported to be 
significantly present in the developing forebrain of 
mice (67). IGFBPL-1 was found to be down-regulated 
in breast cancer (66) and that the methylation of 
IGFBPL-1 was associated with a lower OS and DFS 
in breast cancer patients. In our report, the expression 
of IGFBPL1 was indeed lower in the LVI-PNI+ group, 
but there were no significant methylation patterns 
observed. Furthermore, the IGFL4 gene, which is part 
of the small IGFL family, was also down-regulated in 
the LVI-PNI+ group (68). The specific function of 
IGFL4 has not been reported elsewhere, but it has been 
shown to be expressed in the cerebellum (68).  
 
Interestingly, there were no overlapping genes found 
in between the 2 sets of genes. This suggests that 
cancer cells undergoing PNI only, have a different 
regulation than cells undergoing both LVI and PNI. 
This suggests that the regulation of cancer cells in LVI 
and PNI is more complex than just the elevated 
expression of the predicted invasion-related genes. 
Moreover, in between the LVI-PNI+ and LVI+PNI- 
group, there are 9 overlapping genes, but since the P 
value set for the LVI+PNI- group was P≤0.1, there 
could only be a weak association between the genes.  
 
Furthermore, we performed gene ontology and 
pathway enrichment analyses for the DEGs found in 
the LVI+PNI+ vs LVI-PNI- group. We did not find 
any significantly enriched pathways which suggest 
that the LVI and PNI processes are dependent of each 
other. There is no particular pathway that could lead to 
both the concomitant existence of LVI and PNI in 
CRC. Targeting specific molecules that are 
deregulated in the presence of both LVI and PNI could 
be more feasible than targeting specific pathways. 
Meanwhile, for the LVI-PNI+ vs LVI-PNI- 
comparison, the pathways that were enriched include 
the MAPK and PI3K-AKT pathway. This is in 
concordance with the genes that were significantly 
deregulated, especially PTPRR and FGF20, where 





In summary, the comparison of LVI+PNI+ vs LVI-
PNI- showed that most of the DEGs found were 
related to cell metastasis and angiogenesis. 
Interestingly, there were some contrasting evidence 
found between the expression of these genes in our 
analysis and previously reported studies. This 
indicates that CRC is a molecularly heterogeneous 
disease and different cases of cancer have different 
gene expression profiles.  
 
Nevertheless, the information retrieved from this part 
of the study could have further implications for 
LVI+PNI+ patients. Some of the most deregulated 
DEGs (PTPRR, FGF20, IGFBPL1 and IGFL4) found 
in the LVI-PNI+ vs LVI-PNI- comparison were 
related to neural network, which is highly probable 
since perineural invasion takes place mostly around 
the neural-related areas. These findings could be of 
further use to the treatment of PNI positive CRC 
patients. Collectively, our results show that though 
there were no significant difference in the methylation 
and miRNA profiles, there are some DEGs that could 
be useful for the LVI+PNI+ and LVI-PNI+ patients. 
However, further in-depth study is needed to actually 




address the effects of these genes to the overall 
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